Flanagan W. Michael's Form 4 filing
Avidity Biosciences, Inc. · filed Jan 23, 2024
- Accession no.
- 0001599901-24-000010
- Filed
- Jan 23, 2024
- Trade date
- Jan 20-22, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $41.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Flanagan W. MichaelCIK 0001841990 | Officer (CSTO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 20, 2024 | Common Stock | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 20,290 | Direct | |
| Jan 22, 2024 | Common Stock | SSaleDisposed | −4,129 | $10.13 | −$41,826.77 | 35,871 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 20, 2024 | Common Stock | AGrant or awardAcquired | +88,000 | $0.00 | $0 | 88,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.